Sigilon Therapeutics, Inc. Uncategorized Contracts & Agreements

12 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Form of Contingent Value Right Agreement, by and among Eli Lilly and Company and a rights agent selected by Eli Lilly and Company and reasonably acceptable to Sigilon...
Sigilon Therapeutics, Inc.
Biotechnology
DE
2023
Offer Letter, between Sigilon Therapeutics, Inc. and Josias Pontes, dated October 23, 2019
Sigilon Therapeutics, Inc.
Biotechnology
2023
Offer Letter, between Sigilon Therapeutics, Inc. and Sarah Yuan, dated January 12, 2022
Sigilon Therapeutics, Inc.
Biotechnology
MA
2023
Letter Agreement, dated February 10, 2023, between the Company and May Orfali, M.D
Sigilon Therapeutics, Inc.
Biotechnology
MA
2023
Letter Agreement, dated August 4, 2021, between the Company and Deya Corzo, M.D
Sigilon Therapeutics, Inc.
Biotechnology
2022
Offer Letter, between Sigilon Therapeutics, Inc. and Deya Corzo, M.D. dated September 26, 2018
Sigilon Therapeutics, Inc.
Biotechnology
2022
Offer Letter, between Sigilon Therapeutics, Inc. and Philip Ashton-Rickardt, dated May 25, 2021
Sigilon Therapeutics, Inc.
Biotechnology
MA
2022
Offer Letter, between Sigilon Therapeutics, Inc. and May Orfali, M.D. dated October 27, 2021
Sigilon Therapeutics, Inc.
Biotechnology
MA
2022
Description of Registered Securities
Sigilon Therapeutics, Inc.
Biotechnology
2021
Offer Letter, between Sigilon, Inc. and Devyn Smith, dated March 25, 2017
Sigilon Therapeutics, Inc.
Biotechnology
2020
Offer Letter, between Sigilon Therapeutics, Inc. and Glenn Reicin, dated May 8, 2019
Sigilon Therapeutics, Inc.
Biotechnology
2020
Offer Letter, between Sigilon Therapeutics, Inc. and Rogerio Vivaldi Coelho, M.D., dated April 23, 2018
Sigilon Therapeutics, Inc.
Biotechnology
2020